Multisystem Inflammatory Syndrome in Children

J Emerg Med. 2022 Jan;62(1):28-37. doi: 10.1016/j.jemermed.2021.07.070. Epub 2021 Sep 17.

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a newly recognized condition affecting children with recent infection or exposure to coronavirus disease 2019 (COVID-19). MIS-C has symptoms that affect multiple organs systems, with some clinical features resembling Kawasaki disease (KD) and toxic shock syndrome (TSS).

Objective of the review: Our goal was to review the current literature and describe the evaluation and treatment algorithms for children suspected of having MIS-C who present to the emergency department.

Discussion: MIS-C has a wide clinical spectrum and diagnosis is based on a combination of both clinical and laboratory findings. The exact mechanism of immune dysregulation of MIS-C is not well understood. Physical findings may evolve and do not necessarily appear at the same time. Gastrointestinal, cardiac, inflammatory, and coagulopathy manifestations and dysfunction are seen frequently in MIS-C.

Conclusions: The diagnosis of MIS-C is based on clinical presentation and specific laboratory findings. In the emergency setting, a high level of suspicion for MIS-C is required in patients exposed to COVID-19. Early diagnosis and prompt initiation of therapy offer the best chance for optimal outcomes.

Keywords: COVID-19; Kawasaki disease; PMIS; SARS-CoV-2; multisystem inflammatory syndrome in children.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Child
  • Humans
  • Mucocutaneous Lymph Node Syndrome*
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome / diagnosis
  • Systemic Inflammatory Response Syndrome / etiology

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related